Clinical Trial Update: Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase I safety and dosimetry study in patients with metastatic melanoma conducted by Molecular Insight Pharmaceuticals, Inc. has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Molecular Insight Pharmaceuticals, Inc. | Conditions: Metastatic Melanoma | Phase 1 | Status: TERMINATED